Abstract #2885

Potential anti-HER2 target therapy beneficiaries: can MRI radiomics identify the status of HER2-low in breast cancer?

Xiaoqian Bian¹, Zhibin Yue², Siyao Du¹, Yan Xu³, Yang Song³, Min Zhao⁴, and Lina Zhang¹

¹The First Hospital of China Medical University, Shenyang, China, ²Department of Biomedical Engineering, School of Intelligent Medicine, China Medical University, Shenyang, China, ³MR Scientific Marketing, Siemens Healthineers, Shanghai, China, ⁴Pharmaceutical Diagnostics, GE Healthcare, Beijing, China

Synopsis

Keywords: Radiomics, BreastRecently, HER2-low expression tumor was proposed as a new entity in the field of breast cancer and radiomics studies related to HER2-low are rare. This study investigated whether multiparametric MRI-based radiomics can distinguish HER2- low from HER2-positive and HER2-zero in breast cancer. Results showed that clinico-radiomics nomograms including hormone receptor status and radiomics signatures combined contrast-enhanced T1-weighted and apparent diffusion coefficient map performed best in both prediction tasks: HER2-positive vs. HER2-negative and HER2-low vs. HER2-zero. This suggests that multiparametric MRI radiomics achieved effective prediction of HER2-low, which might be further guidance of the anti-HER2 targeted therapy in breast cancer.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.